Nanoparticle-mediated delivery of Neurotoxin-II to the brain with intranasal administration: An effective strategy to improve antinociceptive activity of Neurotoxin

Drug Development and Industrial Pharmacy

Volumn 38, Issue 1, 2012, Pages 123-128

  Ruan, Yeping ^a   Yao, Li ^a   Zhang, Bingbing ^a   Zhang, Shuijuan ^a   Guo, Jianyou ^b  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF PSYCHOLOGY   (China)

Author keywords

Bloodbrain barrier; Central nervous system; Drug loading; Nasal delivery; Polysorbate 80

Indexed keywords

ANALGESIC AGENT; NANOCARRIER; NEUROTOXIN; NEUROTOXIN II; POLYSORBATE 80; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TRANSPORT; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NANOFABRICATION; NONHUMAN; PAIN; PARTICLE SIZE; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ADMINISTRATION, INTRANASAL; ANALGESICS; ANIMALS; BLOOD-BRAIN BARRIER; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FEMALE; MALE; MICE; NANOPARTICLES; NEUROTOXINS; PARTICLE SIZE; PERMEABILITY; POLYSORBATES;

EID: 82455168235     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.592533     Document Type: Article

References (34)

1. DiNunzio JC, Williams RO 3rd. (2008). CNS disorders-current treatment options and the prospects for advanced therapies. Drug Dev Ind Pharm, 34:1141-1167.
2. Lambert DM. (2000). Rationale and applications of lipids as prodrug carriers. Eur J Pharm Sci, 11 Suppl 2:S15-S27.
3. Bodor N, Buchwald P. (1999). Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev, 36(2-3):229-254.
4. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. (2007). Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev, 59:454-477.
5. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA. (2008). Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv, 5:155-174.
6. Lockman PR, Mumper RJ, Khan MA, Allen DD. (2002). Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm, 28:1-13.
7. Jiang L, Gao L, Wang X, Tang L, Ma J. (2010). The application of mucoadhesive polymers in nasal drug delivery. Drug Dev Ind Pharm, 36:323-336.
8. Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci, 11:1-18.
9. Illum L. (2004). Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol, 56:3-17.
10. Cura JE, Blanzaco DP, Brisson C, Cura MA, Cabrol R, Larrateguy L et al. (2002). Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer. Clin Cancer Res, 8:1033-1041.
11. Zhang HL, Han R, Chen ZX, Chen BW, Gu ZL, Reid PF, et al. (2006). Opiate and acetylcholine-independent analgesic actions of crotoxin isolated from crotalus durissus terri?cus venom. Toxicon, 48:175-182.
12. Tsetlin V. (1999). Snake venom alpha-neurotoxins and other 'three-finger' proteins. Eur J Biochem, 264:281-286.
13. Lu QM, Meng QX, Li DS, Zhu SW, Jia WH, Xiong YL, et al. (2002). Comparative study of three short-chain neurotoxins from the venom of Naja kaouthia (Yunnan, China). J Nat Toxins, 11: 221-229.
14. Tu AT. (1973). Neurotoxins of animal venoms: snakes. Annu Rev Biochem, 42:235-258.
15. Yang CC. (1974). Chemistry and evolution of toxins in snake venoms. Toxicon, 12:1-43.
16. Rang HP. (1974). Acetylcholine receptors. Q Rev Biophys, 7:283-399.
17. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch- Brandt C et al. (2002). Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target, 10:317-325.
18. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS et al. (2004). Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer, 109:759-767.
19. Cheng Q, Feng J, Chen J, Zhu X, Li F. (2008). Brain transport of Neurotoxin-I with PLA nanoparticles through Intranasal Administration in Rats: A Microdialysis Study. Biopharm Drug Dispos, 29:431-439.
20. Huang G, Zhang N, Bi X, Dou M. (2008). Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. Int J Pharm, 355:314-320.
21. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. (2008). Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res, 1200:159-168.
22. Löbenberg R, Araujo L, von Briesen H, Rodgers E, Kreuter J. (1998). Body distribution of azidothymidine bound to hexylcyanoacrylate nanoparticles after i.v. injection to rats. J Control Release, 50:21-30.
23. Fasmer OB, Berge OG, Hole K. (1985). Changes in nociception after lesions of descending serotonergic pathways induced with 5,6-dihydroxytryptamine. Different effects in the formalin and tail-flick tests. Neuropharmacology, 24:729-734.
24. Hunskaar S, Hole K. (1987). The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain, 30:103-114.
25. Yan Z, Wang YP, Jiao CJ, Li FM, Liang YM, Li ZX. (2005) Highperformance liquid chromatographic analysis of neurotoxinβ-N-oxalyl-α, β-diaminopropionic acid (β-ODAP), its nonneurotoxic isomer α-ODAP and other free amino acids in Lathyrus sativus. Chromatographia, 61(5-6): 231-236.
26. Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev, 47:65-81.
27. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch- Brandt C, Alyautdin R. (2002). Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target, 10:317-325.
28. Dyer AM, Hinchcliffe M, Watts P, Castile J, Jabbal-Gill I, Nankervis R et al. (2002). Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res, 19:998-1008.
29. Cui Z, Mumper RJ. (2002). Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses. J Pharm Pharmacol, 54:1195-1203.
30. Lemarchand C, Gref R, Couvreur P. (2004). Polysaccharidedecorated nanoparticles. Eur J Pharm Biopharm, 58: 327-341.
31. Croy JE, Brandon T, Komives EA. (2004). Two apolipoprotein E mimetic peptides, ApoE(130-149) and ApoE(141-155)2, bind to LRP1. Biochemistry, 43:7328-7335.
32. Dergunov AD. (2004). Apolipoprotein E structure and substrate and receptor-binding activities of triglyceride-rich human plasma lipoproteins in normo- and hypertriglyceridemia. Biochemistry Mosc, 69:720-737.
33. Kreuter J. (2004). Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol, 4:484-488.
34. Hosseinzadeh H, Ramezani M, Salmani G. (2000). Antinociceptive, anti-inflammatory and acute toxicity effects of Zataria multiflora Boiss extracts in mice and rats. J Ethnopharmacol, 73: 379-385.